Our Science

Superior technology, targets, target binders and modular constructs for cell therapy


Our unique approach to tumor cell targeted killing has the potential to create breakthrough therapies to treat most cancer patients by identifying targets that unequivocally distinguish tumor from normal cells. We do this in two ways: by addressing targets either lost or gained in cancer cells. 

Targets lost

We also focus on targets that are irreversibly lost in tumor cells by employing a much more powerful version of the mechanism used by natural killer cells. Loss of chromosomal material leads to hemizygosity of large regions of the genome. This provides the potential to address a large patient population (e.g., in the US more than 300,000 cancer patient deaths per year).

Targets gained

We focus on "magic bullet" peptide MHC (pMHC)  targets (e.g., shared neo-antigens). pMHCs are generated inside the cell and presented on the cell surface, providing the potential to access intracellular targets. These pMHCs are the T cell's natural targets and are scrutinized by T cells to discriminate friend from foe.

Technology platform

A2 leverages a powerful platform that enables identification of rare binders derived from antibodies or TCRs, precision binder engineering and optimization, and modular design. We have potent binders (antibody and TCR fragments that bind to the target) with exquisite selectivity, and modular constructs under development that integrate multiple signals and potentially provide a large therapeutic window.


Our platform technologies under development include:

  • Assays that quantify T cell proliferation, cytotoxicity and survival either acutely or over time

  • A high-throughput selection system that enables us to enrich based on binding or function, giving us the flexibility to optimize the most important parameters of cell therapy

  • Modular constructs that integrate multiple signals to potentially provide a large therapeutic window

  • Two major types of signal integration: 1) molecular integrator with a single bispecific molecule; and 2) cellular integrator with two independent modules


A component of the platform, the HuTARGTM technology, is licensed from Innovative Targeting Solutions (Vancouver, British Columbia). 

Pipeline focused on solid tumor targets

Ongoing innovation

In addition to discovery research, we are planning to innovate in manufacturing. Our autologous cell manufacturing facility will be operational in 2021 with technology scalable for commercial launch.

We aspire to increase speed to patients and reduce cost of goods by advancing the technology and leveraging our cell therapy manufacturing expertise.


30301 Agoura Road #210, Agoura Hills, CA, 91301


© 2019 A2 Biotherapeutics, Inc.